Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07210554) titled 'Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid' on Sept. 30.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).

Primary Sponsor: Chengdu Kangnuoxing Biopharma,Inc.

Condition: Bullous Pemphigoid (BP)

Intervention: Biological: Stapokibart injection

Recruitment Status: Not recruiting

Phase: Phase 3

Date of First Enrollment: November 11, 2025

Target Sample Size: 200

Countries of Recruitment: China

To know...